Skip to main content

Acne Vulgaris

166
Pipeline Programs
30
Companies
50
Clinical Trials
4 recruiting
8
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
22
4
26
1
58
55
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
675%
Monoclonal Antibody
113%
Peptide
113%
+ 213 programs with unclassified modality

On Market (8)

Approved therapies currently available

Leo Pharma
FINACEAApproved
azelaic acid
Leo Pharma
topical2015
2M Part D
Almirall
SEYSARAApproved
sarecycline hydrochloride
Almirall
oral2018
658K Part D
EPSOLAYApproved
benzoyl peroxide
Unknown Company
topical2022
438K Part D
Galderma
AKLIEFApproved
trifarotene
Galderma
Retinoid [EPC]topical2019
198K Part D
Galderma
DIFFERINApproved
adapalene
Galderma
Retinoid [EPC]topical2007
94K Part D
Almirall
ACZONEApproved
dapsone
Almirall
Sulfone [EPC]topical2016
89K Part D
Bayer
YAZApproved
drospirenone and ethinyl estradiol
Bayer
oral2006
Bayer
YASMINApproved
drospirenone and ethinyl estradiol
Bayer
oral-282001

Competitive Landscape

43 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
37 programs
13
1
8
14
BENZOYL PEROXIDE/ CLINDAMYCINPhase 4
Clindamycin + BPOPhase 4
Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotenePhase 4
Clindamycin and BPO 5% gelPhase 4
Clindamycin and benzoyl peroxidePhase 4
+32 more programs
Galderma
GaldermaTX - Dallas
36 programs
3
16
15
ABPO Forte GelPhase 41 trial
AdapalenePhase 41 trial
Adapalene + benzoyl peroxide samplesPhase 41 trial
Adapalene 0.1% and Benzoyl Peroxide 2.5% gelPhase 41 trial
Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gelPhase 41 trial
+31 more programs
Active Trials
NCT02338544Completed1,388Est. Sep 2015
NCT01618773Completed6,036Est. Sep 2013
NCT02073461Completed236Est. Oct 2014
+33 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
19 programs
4
1
6
8
ACZONE Gel, 5%Phase 41 trial
DapsonePhase 41 trial
Dapsone GelPhase 41 trial
Dapsone plus AdapalenePhase 41 trial
Dapsone; TretinoinPhase 41 trial
+14 more programs
Active Trials
NCT02218034Completed78Est. Mar 2015
NCT01773122Completed77Est. May 2013
NCT01785836Withdrawn0Est. Oct 2013
+16 more trials
Bayer
BayerLEVERKUSEN, Germany
10 programs
6
2
Azelaic acidPhase 41 trial
skinorenPhase 41 trial
Azelaic Acid Gel 15%Phase 3
EE20/DrospirenonePhase 31 trial
ValettePhase 31 trial
+5 more programs
Active Trials
NCT02349399Completed26,065Est. Mar 2016
NCT02410031Completed759Est. Mar 2016
NCT00818519Completed179Est. May 2010
+6 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
9 programs
2
3
1
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.Phase 41 trial
IDP-120Phase 31 trial
IDP-123Phase 32 trials
IDP-126Phase 3
1.2% JNJ 10229570-AAAPhase 21 trial
+4 more programs
Active Trials
NCT00795327Completed22Est. Sep 2009
NCT07205107Active Not Recruiting200Est. Aug 2026
NCT01326780Completed431Est. Mar 2012
+5 more trials
Vyne Therapeutics
1
1
2
3
1
IsotretinoinPhase 41 trial
FMX-101, 4% minocycline foamPhase 31 trial
FMX-101, 4% minocycline foamPhase 31 trial
FMX101Phase 31 trial
FCD105Phase 21 trial
+3 more programs
Active Trials
NCT03743038Completed12Est. Feb 2019
NCT01494285Completed157Est. Oct 2013
NCT04104685Completed446Est. Mar 2020
+5 more trials
Almirall
5 programs
1
2
1
dapsone gelPhase 4
Dapsone GelPhase 3
Dapsone GelPhase 3
50 mg P005672-HClPhase 2
SEYSARA(sarecycline)Phase N/ASmall Molecule3 trials
Active Trials
NCT07544251Recruiting30Est. Jun 2027
NCT04820673Completed300Est. May 2022
NCT05010538Completed10Est. Aug 2021
Biocorp
3 programs
1
1
1
clindamycinPhase 41 trial
ALA 2.5%Phase 1/21 trial
ALA 5%Phase 11 trial
Active Trials
NCT04044898Completed19Est. Dec 2021
NCT04018885Completed72Est. Jan 2020
NCT00219570Completed134Est. Jun 2005
Maruho
3 programs
2
1
Erythromycin 4% topical gel formulationPhase 4
CLS001 Topical GelPhase 21 trial
OmigananPhase 21 trial
Active Trials
NCT02066545Completed327
NCT02571998Completed320Est. Aug 2016
Leo Pharma
Leo PharmaDenmark - Ballerup
3 programs
2
1
1
Azelaic Acid Gel 15%Phase 31 trial
LEO43204Phase 21 trial
marketed topical retinoidPhase 21 trial
Active Trials
NCT02575950Completed59Est. Apr 2017
NCT01461655Completed40Est. May 2012
NCT00031096Completed879Est. Jul 2002
Avenue Therapeutics
1
zinc gluconatePhase 41 trial
Whole blood zinc levelN/A1 trial
Active Trials
NCT04975412Completed40Est. Mar 2018
NCT05096312Completed23Est. Jul 2019
Pfizer
PfizerNEW YORK, NY
2 programs
1
1
clindamycinPhase 4
PF-05175157Phase 21 trial
Active Trials
NCT02100527Withdrawn0Est. Oct 2014
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
Erythromycin 4% topical gel formulationPhase 41 trial
Active Trials
NCT03883269Recruiting30Est. Dec 2019
Prevail Therapeutics
1
1
1
3
Olumacostat Glasaretil Gel, 5.0%Phase 31 trial
Olumacostat Glasaretil Gel, 5.0%Phase 31 trial
Olumacostat Glasaretil Gel, 5.0%Phase 31 trial
Olumacostat GlasaretilPhase 21 trial
Olumacostat Glasaretil Gel, 7.5%Phase 1/21 trial
+1 more programs
Active Trials
NCT01830764Completed12Est. Jun 2013
NCT01936324Completed114Est. Jun 2014
NCT02431052Completed420Est. Apr 2016
+3 more trials
Dr. Reddy's Laboratories
4 programs
2
2
DFD-03Phase 31 trial
DFD-03Phase 31 trial
DFD-03 Lotion, 0.1%Phase 21 trial
Tazarotene Lotion, 0.1%Phase 21 trial
Active Trials
NCT03341910Completed155Est. May 2018
NCT03599193Completed58Est. Apr 2018
NCT03290027Completed550Est. Apr 2018
+1 more trials
Sunshine Biopharma
1
2
1% Clascoterone CreamPhase 31 trial
ClascoteronePhase 31 trial
Clascoterone Cream 1%Phase 11 trial
Active Trials
NCT06454708Completed12Est. Aug 2024
NCT07457294Not Yet Recruiting692Est. Feb 2029
NCT06403501Recruiting692Est. Oct 2026
Dermata Therapeutics
3 programs
2
1
DMT310Phase 31 trial
DMT310Phase 21 trial
DMT310Phase 21 trial
Active Trials
NCT04106778Completed181Est. May 2020
NCT03536637Completed121Est. Jan 2019
NCT06090721Completed520Est. Apr 2025
Ache Laboratorios Farmaceuticos
2
Adapalene + Benzoyl PeroxidePhase 3
Adapalene and Benzoyl peroxide Dalap Duo®Phase 31 trial
Active Trials
NCT02716090Withdrawn0
Aurobindo Pharma
Aurobindo PharmaIndia - Hyderabad
1 program
1
AdapalenePhase 31 trial
Active Trials
NCT04329403Withdrawn0Est. May 2021
Zhaoke Ophthalmology
Zhaoke OphthalmologyChina - Guangzhou
1 program
1
Adapalene-Clindamycin Combination GelPhase 3
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
BaidI Quzhi granulePhase 31 trial
Active Trials
NCT05035979Unknown472Est. Aug 2023
Angeles Therapeutics
1
CalcipotrienePhase 2/31 trial
HBKB CapsuleN/A1 trial
Active Trials
NCT04534140Withdrawn0Est. Jan 2023
NCT01694433Completed66Est. Jan 2014
Biofrontera
BiofronteraGermany - Leverkusen
1 program
1
1h Incubation Photodynamic therapyPhase 21 trial
Active Trials
NCT05080764Active Not Recruiting126Est. Jan 2026
Clinuvel Pharmaceuticals
1
AfamelanotidePhase 2Peptide1 trial
Active Trials
NCT04943159Completed3Est. Mar 2011
BioMimetix JV
1 program
1
BMX-010 0.3%Phase 21 trial
Active Trials
NCT03752242Terminated2Est. Aug 2020
Botanix Pharmaceuticals
Botanix PharmaceuticalsAustralia - West Perth
1 program
1
BTX 1503Phase 21 trial
Active Trials
NCT03573518Completed368Est. Sep 2019
Sandoz
SandozAustria - Kundl
1 program
1
CJM112Phase 21 trial
Active Trials
NCT02998671Completed52Est. Aug 2018
Vyome Therapeutics
1
VB-1953 - 2%Phase 21 trial
Active Trials
NCT03900676Unknown480Est. Mar 2020
Next Science
Next ScienceAustralia - Sydney
2 programs
1
1
Next Science Acne GelPhase 1/21 trial
Acne cream 2XPhase 11 trial
Active Trials
NCT03106766Terminated2Est. Aug 2017
NCT02404285Completed68Est. Sep 2015
GSK
GSKLONDON, United Kingdom
35 programs
acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%N/A1 trial
0.3% GSK1940029 gelPHASE_11 trial
0.3% GSK1940029 gelPHASE_11 trial
CT GelPHASE_11 trial
Clindamycin 1%-Benzoyl PeroxidePHASE_11 trial
+30 more programs
Active Trials
NCT01446237Completed125Est. Dec 2011
NCT01938482Completed55Est. Feb 2015
NCT01984801Completed54Est. Apr 2015
+32 more trials

+13 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Almirallsarecycline
Bausch HealthCABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
GaldermaTrifarotene Cream
Vyne TherapeuticsIsotretinoin
GaldermaTrifarotene Cream
GaldermaTrifarotene cream
Avenue Therapeuticszinc gluconate
Human BioSciencesErythromycin 4% topical gel formulation
AbbViedapsone gel
GaldermaAdapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
GaldermaABPO Forte Gel
GaldermaBenzoyl Peroxide
GaldermaAdapalene/benzoyl peroxide gel, 0.1%/2.5%
GSKClindamycin + BPO
AbbVieDapsone Gel

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 6,375 patients across 50 trials

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

Start: Apr 2026Est. completion: Jun 202730 patients
Phase 4Recruiting
NCT07524946Bausch HealthCABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

Start: Apr 2026Est. completion: Dec 2027100 patients
Phase 4Not Yet Recruiting
NCT05089708GaldermaTrifarotene Cream

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Start: Dec 2021Est. completion: Dec 2022123 patients
Phase 4Completed

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

Start: Jun 2021Est. completion: Apr 202331 patients
Phase 4Completed
NCT04856904GaldermaTrifarotene Cream

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Start: May 2021Est. completion: Jun 2023121 patients
Phase 4Completed
NCT04451330GaldermaTrifarotene cream

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

Start: Jul 2020Est. completion: Apr 2021202 patients
Phase 4Completed

Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients

Start: Dec 2018Est. completion: Jul 201923 patients
Phase 4Completed
NCT03883269Human BioSciencesErythromycin 4% topical gel formulation

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Start: Mar 2018Est. completion: Dec 201930 patients
Phase 4Recruiting

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Start: Oct 2016Est. completion: Mar 2018100 patients
Phase 4Completed
NCT02899000GaldermaAdapalene 0.3% / benzoyl peroxide 2.5% emulsion gel

A Treatment for Severe Inflammatory Acne Subjects

Start: Jul 2016Est. completion: Jun 2017186 patients
Phase 4Completed
NCT02735421GaldermaABPO Forte Gel

Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars

Start: May 2016Est. completion: Nov 201767 patients
Phase 4Completed
NCT02589405GaldermaBenzoyl Peroxide

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Start: Aug 2015Est. completion: Jan 201650 patients
Phase 4Completed
NCT02249104GaldermaAdapalene/benzoyl peroxide gel, 0.1%/2.5%

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris

Start: Aug 2014Est. completion: Feb 201528 patients
Phase 4Completed
NCT02058628GSKClindamycin + BPO

Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris

Start: Feb 2014Est. completion: Sep 2014222 patients
Phase 4Completed

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

Start: Dec 2013Est. completion: Sep 201468 patients
Phase 4Completed

Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel

Start: Apr 2012Est. completion: May 201273 patients
Phase 4Completed
NCT01504204GaldermaAdapalene + benzoyl peroxide samples

Effect of Samples on Acne Treatment With Epiduo® Gel

Start: Dec 2011Est. completion: Nov 201220 patients
Phase 4Completed

Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin

Start: Aug 2011Est. completion: Oct 201260 patients
Phase 4Completed
NCT01209949GaldermaAdapalene 0.1% and Benzoyl Peroxide 2.5% gel

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Start: Oct 2010Est. completion: Jan 201130 patients
Phase 4Completed
NCT01231334AbbVieDapsone plus Adapalene

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne

Start: Aug 2010Est. completion: Jun 2011286 patients
Phase 4Completed
NCT01149330GaldermaAdapalene-BPO Gel

Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

Start: Jul 2010Est. completion: Apr 201175 patients
Phase 4Completed

Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel

Start: Mar 2010Est. completion: Aug 201040 patients
Phase 4Completed
NCT01038869BayerAzelaic acid

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)

Start: Dec 2009Est. completion: May 201020 patients
Phase 4Completed
NCT01016977GSKClindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene

A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

Start: Oct 2009Est. completion: Apr 201040 patients
Phase 4Completed
NCT01706250GSKMAXCLARITY II

U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™

Start: Sep 2009Est. completion: Jan 201020 patients
Phase 4Completed
NCT02524665GSKMAXCLARITY II

8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne

Start: Sep 2009Est. completion: Dec 200920 patients
Phase 4Completed
NCT01706263GSKMAXCLARITY II

U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne

Start: Aug 2009Est. completion: Nov 200928 patients
Phase 4Completed
NCT01015638GSKClindamycin and BPO 5% gel

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

Start: Aug 2009Est. completion: Sep 200936 patients
Phase 4Completed
NCT00964366GSKclindamycin and benzoyl peroxide

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

Start: Jul 2009Est. completion: Aug 200953 patients
Phase 4Completed
NCT00964223GSKClindamycin and benzoyl peroxide gel

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

Start: Jul 2009Est. completion: Nov 200928 patients
Phase 4Completed
NCT00926367GSKClindamycin and benzoyl peroxide

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

Start: May 2009Est. completion: Jul 200952 patients
Phase 4Completed
NCT00887484GSKBENZOYL PEROXIDE/ CLINDAMYCIN

A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne

Start: Feb 2009Est. completion: Jun 200950 patients
Phase 4Completed

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

Start: Dec 2008Est. completion: Sep 2009171 patients
Phase 4Completed
NCT00835198AbbVieDapsone; Tretinoin

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

Start: Dec 2008Est. completion: Aug 2009163 patients
Phase 4Completed
NCT00757523GSKEpiduo Gel

Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris

Start: Sep 2008Est. completion: Jun 2009382 patients
Phase 4Completed

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Start: May 2008Est. completion: Nov 200851 patients
Phase 4Completed
NCT00671749Galdermaadapalene gel, 0.3%

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

Start: Dec 2007Est. completion: Aug 2008100 patients
Phase 4Completed
NCT00829049AbbVieTazarotene Cream 0.1%

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

Start: Oct 2007Est. completion: Oct 2008165 patients
Phase 4Terminated

Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne

Start: Nov 2006Est. completion: Aug 2008169 patients
Phase 4Completed
NCT00469755GaldermaAdapalene Gel, 0.1%

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

Start: Feb 2006Est. completion: Sep 2006302 patients
Phase 4Completed
NCT00243542AbbVieACZONE Gel, 5%

Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency

Start: Nov 2005Est. completion: Oct 200664 patients
Phase 4Completed
NCT00377000Sanoficlindamycin 1% / benzoyl peroxide 5% gel pump

A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.

Start: Nov 2005Est. completion: Mar 200660 patients
Phase 4Completed

Dalacin-T Gel Post Approval Study

Start: Jan 2005Est. completion: Jun 2005134 patients
Phase 4Completed
NCT00160394GSKDuac® Gel / Differin® Gel

Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris

Start: Dec 2004Est. completion: Aug 2005130 patients
Phase 4Completed
NCT00240513GSKMinocycline

Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin

Start: Aug 2004Est. completion: Dec 200638 patients
Phase 4Terminated
NCT00145106AbbVieTazarotene 0.1% gel + placebo capsule, Oral minocycline

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

Start: Mar 2002Est. completion: Aug 2002189 patients
Phase 4Completed
NCT02716090Ache Laboratorios FarmaceuticosAdapalene and Benzoyl peroxide Dalap Duo®

Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris

0
Phase 3Withdrawn
NCT07457294Sunshine Biopharma1% Clascoterone Cream

1% Clascoterone Cream for the Treatment Acne Vulgaris

Start: May 2026Est. completion: Feb 2029692 patients
Phase 3Not Yet Recruiting

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Start: Sep 2025Est. completion: Dec 2026561 patients
Phase 3Recruiting

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Start: May 2024Est. completion: Oct 2026692 patients
Phase 3Recruiting

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

58 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 6,375 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.